Regulatory Focus

CBER Plots New Draft Guidance in 2020 on Genome Editing, CAR-T Therapies

14 February 2020 | By Zachary Brennan 

The FDA’s Center for Biologics Evaluation and Research (CBER) unveiled its 2020 guidance list on Friday, with new drafts coming on s...

Regulatory Exchange